Anemia Clinical Trial
Official title:
Chengdu Women's and Children's Central Hospital
The present study is intended to supplement the preschool anemic children with vitamin A capsule and de-hookworm administration in poverty Sichuan province. We eventually expect our study can provide a cost-effective, safe and more beneficial public health strategy to manage the anemia status of preschool children in poverty area.
Subjects and ethical approval This randomized, control and double-blinded cohort study was
performed in Dayi, Pixian and Meishan country, Sichuan Province, western China, which are
suburbs of Chengdu city with a low class of socioeconomic status, from March 2012 to
September 2014 and approximately about 216 anemic preschool children aged 3-6 years were
randomly recruited from nine kindergartens of the three countries for the study during
intervention period. The eligibility criteria for participation were as follows: 1) apparent
health; 2) Hb concentration <110 g/l but not <80 g/l; 3) C-reaction protein (CRP) <10 mg/L;
4) parental or guardian approval of participation in all aspects of the study; and 5)
parental/guardian agreement to avoid the additional use of vitamin and mineral supplements
and de-hookworm administration during the trial. Children with Hb<80 g/l and /or CRP >10
mg/l were sent to hospital with special treatment.
We conducted a census in each regional kindergarten to determine which households included
an eligibility preschool children. Then field health workers conducted a family survey to
determine which children was included. Eligible families were visited by a field worker who
explained the protocol, answered questions, and obtained written informed consent from
parents/guardians. The enrollment and research plan were reviewed and approved by the
institutional ethics committee of the Chengdu Women's and Children's Central Hospital of
Chongqing Medical University in Sichuan province, China. The present study complied with the
code of ethics of the World Medical Association (Declaration of Helsinki).
The primary objective for the present study was to measure the change in serum Hb before and
after intervention. A sample size of about 60 anemic preschool children per group was
required to detect an absolute difference of 10 g/L of Hb concentration among three
intervention groups after supplementation with 95% power and α= 0.05 for a two-sided
two-sample t-test. To allow for 20% rate of dropout over the duration of the study, we
initially planed to recruit about 72 anemic children per group (totally 216). We estimated
that the prevalence of anemia of preschool children in locality was about 16%[17],
eventually about 1350 children were recruited into an initial Hb screening study before
intervention and about 450 for each group.
Intervention All eligible anemic children were randomly divided into three groups: Group 1
was received no intervention as control group; Group 2 was received 400 mg single-dose
albendazole administration and Group 3 was received a 200,000 IU vitamin A capsule combined
400 mg single-dose albendazole once initially. For ethical reason, all of the children in
control group were given a single-dose albendazole at the end of study. Immediately after
recruitment, children in one class were assigned a study number that had been previously
randomly assigned to the intervention or control group with fixed, equal allocation to each
group prepared by a third party. The RAND function of Excel (Microsoft, Redmond, WA, USA)
was used to generate computer randomly permutated codes. The physicians, nurses, field
health workers, parents, children and laboratory personnel were blinded to the treatment
assignment of each child throughout the study period. The data manager, statistician, and
all investigators remained blinded to group assignments until the end of data analysis. The
total duration of intervention and evaluation were six months. Vitamin A capsule and
albendazole tablet were provided by Sichuan Pearl Pharmaceutical Co., Ltd.
Compliance Compliance of albendazole tablet and vitamin A capsule were monitored using
recording tables, in which teachers recorded whether the child consumed "all" or "none" of
the albendazole tablet and vitamin A capsule. To avoid exchange of albendazole tablet and
vitamin A capsule by classmates, the three groups were physically separated by being moved
to opposite corners of the classroom. Distribution and consumption of the albendazole tablet
and vitamin A capsule took place under close supervision; children in group 2 and group 3
were not allowed to leave the classroom or return to their original seats before they had
finished eating their albendazole tablet and vitamin A capsule. The distribution of tablets
was performed by nursery managers, but not health care workers and nursery teachers.
Information on the acceptability of the albendazole tablet and vitamin A capsule was
obtained by a short questionnaire after administered.
Questionnaire interview A 30-minute questionnaire was conducted by a trained interviewer
after recruitment. The questionnaire included questions on demographic information
(children's age, sex), educational levels of main caregivers ( who were at least responsible
for the half of care time of children), monthly family income, use of vitamin/mineral
supplement before trial and food frequency recall (the frequency of deep-colored vegetables
and milk, liver and egg).
Anthropometric measurements Anthropometric examinations were conducted by the same trained
anthropometric nurse at baseline and follow-up (6-mo) time points using standardized
techniques to eliminate intra-examiner error. Duplicate measurements were performed for all
children. The inter-examiner coefficient of variation of weight and height for each examiner
in each group was less than 5%. Weight was recorded using a weighing scale (100Med, Beijing,
China) to the nearest 100 g with subjects in minimal clothing and bare feet. Similarly,
height was measured in the standard position by a height scale (Haode, Guangzhou, China) to
the nearest 0.1 cm. By using reference data from World Health Organization (WHO; 2005), the
Z-scores were calculated for height for age (HAZ), weight for height (WHZ), and weight for
age (WAZ). All indices were computed using Anthro (2005) for the personal computer, as
recommended by the WHO (http://www.who.int/childgrowth/software/en/).
Blood sample collection and biochemical assessment At the beginning and at 3 and 6 month
after intervention, three blood samples (about 1 mL) were collected by venipuncture of an
antecubital vein from each subject before breakfast in hospital. A quarter of a milliliter
was drawn into a container containing heparin to measure Hb by the hemoglobincyanide method
(Maker, Chengdu, China). The interassay variation was lower than 5% and the intra-assay
variation was lower than 10%. The blood samples were immediately stored at 4° C to prevent
micro-hemolysis and were separated within 5 h. The remaining blood was centrifuged at 3000g
for 5 min at room temperature. The centrifuged serum samples were divided into aliquots and
immediately transported to the laboratory and stored at -20°C. The concentrations of serum
ferritin (SF) were measured using a commercial enzyme-linked immunosorbent assay (ELISA)
(Sunbiote, Shanghai, China). Serum soluble transferrin receptor (sTfR) was measured by
microparticle-enhanced immunoassay (Sunbiote, Shanghai, China). CRP was measured by
particle-enhanced immunoturbidimetry (Sunbiote, Shanghai, China). Serum retinol
concentration was determined by using high-performance liquid chromatography. Serum retinol
was measured by experienced examiners in the Pediatric Laboratory of Chongqing Medical
University and the other biochemical indices in Clinical Laboratory Center of Chengdu Women
& Children's Central Hospital.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
Completed |
NCT01432717 -
Study of ACE-536 in Healthy Postmenopausal Women
|
Phase 1 | |
Completed |
NCT01458028 -
Age and Gender Effects on the Pharmacokinetics of BAY85-3934
|
Phase 1 |